前列地尔注射液治疗重度黄疸型病毒性肝炎的效果及对患者血管活性物质的影响

Effect of Alprostadil Injection in the Treatment of Severe Jaundice-Type Viral Hepatitis and the Impact on Patients’ Vasoactive Substances

目的观察前列地尔注射液治疗重度黄疸型病毒性肝炎的效果及对患者血管活性物质的影响。方法46例重度黄疸型病毒性肝炎患者随机均分为两组,对照组采用常规保肝治疗,观察组在此基础上加用前列地尔注射液治疗,比较两组治疗后的肝功能、血管活性物质及不良反应。结果治疗后,观察组的ALT、TBIL、DBIL、PTA水平显著低于对照组(P<0.05)。治疗后,观察组的血浆内皮素水平显著低于对照组,CGRP、NO水平显著高于对照组(P<0.05)。两组的不良反应发生率无统计学差异(P>0.05)。结论在常规保肝治疗的基础上加用前列地尔注射液治疗重度黄疸型病毒性肝炎的临床效果显著,安全性高。

Objective To observe the effect of alprostadil injection in the treatment of severe jaundice-type viral hepatitis and its impact on patients' vasoactive substances. Methods 46 patients with severe jaundice-type viral hepatitis were randomly divided into two groups equally. The control group received conventional hepatoprotective treatment, and the observation group was treated with alprostadil injection on the basis of control group. The liver function, vasoactive substances and adverse reactions after treatment were compared between the two groups. Results After treatment, the levels of ALT, TBIL, DBIL and PTA of observation group were significantly lower than those of control group (P<0.05). After treatment, the level of plasma endothelin of observation group was significantly lower than that of control group, and the levels of CGRP and NO were significantly higher than those of control group (P<0.05). No statistical difference was found in the incidence of adverse reactions between the two groups (P >0.05). Conclusions On the basis of conventional hepatoprotective treatment, alprostadil injection has significant clinical effect and high safety in the treatment of severe jaundice-type viral hepatitis.